Pharmacy in China

Cipher Pharmaceuticals Schedules Q4 2020 Earnings Release and Conference Call

Retrieved on: 
Wednesday, March 10, 2021
Pharmaceuticals policy, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Health care, Health, Pharmacy

Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.

Key Points: 
  • Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products.
  • Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly inCanadaor indirectly through partners inCanada, the U.S., andSouth America.
  • For more information, visit www.cipherpharma.com .

NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration

Retrieved on: 
Tuesday, March 9, 2021
Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Aviptadil

RADNOR, Pa. and AUSTIN,Texas, March 9, 2021 /PRNewswire/ --NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP)are announcing that the companies have entered into a feasibility and material transfer agreement (Feasibility Agreement).

Key Points: 
  • RADNOR, Pa. and AUSTIN,Texas, March 9, 2021 /PRNewswire/ --NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP)are announcing that the companies have entered into a feasibility and material transfer agreement (Feasibility Agreement).
  • Under the Feasibility Agreement, NeuroRx is delivering ZYESAMI (aviptadil, synthetic VIP)materials to TFF in order to perform feasibility formulation work and testing.
  • TFF Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform.
  • This press release contains forward-looking statements regardingTFF Pharmaceuticals, Inc., including the benefits of the Company's TFF platform and a potential its dry powder version of NeuroRx's ZYESAMI.

TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021

Retrieved on: 
Friday, March 5, 2021
Health, Communications, Other Health, General Health, Pharmaceutical, Biotechnology, Public relations, Investor relations, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, TFF Pharmaceuticals’ Thin Film Freezing technology platform, TFF Pharmaceuticals

Glenn Mattes, President & CEO of TFF Pharmaceuticals, is scheduled to give a pre-recorded company presentation at both virtual conferences.

Key Points: 
  • Glenn Mattes, President & CEO of TFF Pharmaceuticals, is scheduled to give a pre-recorded company presentation at both virtual conferences.
  • Additionally, Dr. Dale Christensen, Director of Clinical Development at TFF Pharmaceuticals, will participate in a panel discussion at the ROTH Conference on March 15th at 12pm ET.
  • Recordings of the presentations will be available on-demand to registered conference attendees and can be accessed in the Investor Relations section of the TFF Pharmaceuticals website .
  • TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform.

Rafarma Embarks on Aggressive Global Partnerships Plan

Retrieved on: 
Thursday, March 4, 2021
Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China

Nicosia, Cyprus, March 04, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce its newly formulated strategies for aggressive global growth in 2021/2022.

Key Points: 
  • Nicosia, Cyprus, March 04, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce its newly formulated strategies for aggressive global growth in 2021/2022.
  • The optimal scenario for such promotion is the expansionof collaboration with developers and effective commercial partners in the world market.
  • These collaboration should provide faster access to key global and regional markets for the company's products achieved by contracts for partnership and mutual distribution.
  • In pursuit of these strategies, Rafarma is activelyinvolvedin the process of establishing contractual partnerships with approximately 200 companies in various countries, to be finalized by the summer of 2022.

Acquiring Xiaoer Qingre Zhike granule, Tianda Pharmaceuticals continues to broaden its product mix and perfect its Chinese medicine whole industry chain layout

Retrieved on: 
Thursday, March 4, 2021
Pseudoscience, Alternative medicine, Pharmacy in China, Traditional Chinese medicine, Traditional medicine, Medicine, Health sciences, Health

As a pediatric Chinese medicine for clearing heat and stopping cough, it has a long standing history and has been widely recognized, as well as recommended by Chinese medicine practitioners.

Key Points: 
  • As a pediatric Chinese medicine for clearing heat and stopping cough, it has a long standing history and has been widely recognized, as well as recommended by Chinese medicine practitioners.
  • In addition, as a Chinese proprietary herbal medicine, Xiaoer Qingre Zhike Granule further perfects the Group's Chinese medicine business segment.
  • "This acquisition represents an important step to the Group's continued efforts to broaden its product mix and perfect its Chinese medicine whole industry chain layout.
  • As Chinese medicine continues to gain attention and importance domestically and internationally, the Group remains optimistic on the development of Chinese medicine in the world.

Covectra Strengthens Board of Directors with Two New Key Appointments

Retrieved on: 
Tuesday, March 2, 2021
Pharmaceuticals policy, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Healthcare industry

"On behalf of the entire Board of Directors, it is a pleasure to welcome Renaat and Gary, two highly accomplished industry veterans, to our team," saidSteve Wood, President and Chief Executive Officer of Covectra.

Key Points: 
  • "On behalf of the entire Board of Directors, it is a pleasure to welcome Renaat and Gary, two highly accomplished industry veterans, to our team," saidSteve Wood, President and Chief Executive Officer of Covectra.
  • Mr. Van den Hooff brings to the Covectra Board of Directors over 35 years of global operating experience in the healthcare industry, with specific expertise in consumer pharmaceuticals, medical devices and supplies/services for the pharmaceutical industry.
  • Prior to joining Covectra, he held senior level positions at Fidelity Investments, Health Dialog and American Express.
  • With over 3 billion serial numbers issued worldwide, Covectra helps to combat counterfeiting & product diversion and to facilitate product recalls.

White Oak Healthcare Finance Supports Acquisition of Australian Based Parnell Pharmaceuticals by DW Healthcare

Retrieved on: 
Tuesday, March 2, 2021
Professional services, Health, Finance, General Health, Pharmaceutical, Veterinary, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Healthcare industry

White Oak Healthcare Finance, LLC (White Oak) today announced it acted as sole lender and administrative agent of a senior credit facility to support the acquisition of Parnell Pharmaceuticals Holdings, Ltd. (Parnell) by DW Healthcare Partners (DWHP).

Key Points: 
  • White Oak Healthcare Finance, LLC (White Oak) today announced it acted as sole lender and administrative agent of a senior credit facility to support the acquisition of Parnell Pharmaceuticals Holdings, Ltd. (Parnell) by DW Healthcare Partners (DWHP).
  • Parnell is an Australian based developer, manufacturer and marketer of animal health pharmaceutical products for customers in the US and internationally.
  • It was great to complete another deal with White Oak given their broad and deep experience in the sector.
  • For more information, please visit: parnell.com
    White Oak Healthcare Finance, LLC (WOHCF), an affiliate of White Oak Global Advisors, LLC is a lender to all subsectors within the healthcare industry including healthcare services, pharma and life sciences, medical devices, healthcare technology, healthcare real estate, hospitals and SNFs.

Concert Pharmaceuticals to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, March 2, 2021
General Health, Pharmaceutical, Health, Clinical trials, Life sciences, Health sciences, Biotechnology, Specialty drugs, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Biopharmaceutical

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming virtual investor conferences:

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming virtual investor conferences:
    The H.C. Wainwright Global Life Sciences Conference on March 9, 2021, on-demand beginning at 7:00 a.m.
  • A live webcast of the presentations may be accessed in the Investors section of the Companys website at www.concertpharma.com .
  • Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required.
  • Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform (deuterated chemical entity platform).

Spectrum Pharmaceuticals Announces Poster Presentation at Upcoming Miami Breast Cancer Conference

Retrieved on: 
Friday, February 26, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Health care, Health sciences, Health

This presentation will take place as part of the 38th Annual Miami Breast Cancer Conference taking place virtually March 4-7, 2021.

Key Points: 
  • This presentation will take place as part of the 38th Annual Miami Breast Cancer Conference taking place virtually March 4-7, 2021.
  • Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies.
  • SPECTRUM PHARMACEUTICALS, INC. and ROLONTIS are registered trademarks of Spectrum Pharmaceuticals, Inc and its affiliate.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

TABMELT® Granted Patent Rights in Russia, Expanding Vivera Global Licensing

Retrieved on: 
Thursday, February 25, 2021
Health sciences, Health care, Health, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, Patent, Pharmaceutical industry in India, Pharmaceutical industry

NEWPORT BEACH, Calif., Feb. 25, 2021 /PRNewswire/ -- Vivera Pharmaceuticals, Inc., is pleased to announce the expansion of its exclusive global licensing of the novel TABMELT platform to Russia.

Key Points: 
  • NEWPORT BEACH, Calif., Feb. 25, 2021 /PRNewswire/ -- Vivera Pharmaceuticals, Inc., is pleased to announce the expansion of its exclusive global licensing of the novel TABMELT platform to Russia.
  • The latest TABMELT patent approval comes as the Company begins to expand its pharmaceutical offerings into neuroscience, and joins Canada, the United Kingdom, and Australia as countries that have granted patent rights to the TABMELT sublingual technology.
  • "With the finalization and granting of the long-awaited Russian patent, TABMELT has an even stronger international presence," states Paul Edalat, CEO of Vivera Pharmaceuticals.
  • "With Vivera's exclusive global license of the TABMELT technology for use in pharmaceuticals, we are able to develop better medications for patients at home and abroad.